
Jeffrey Weitz, MD, secretary general of the ISTH, discusses the recent analysis of the AXIOMATIC-TKR trial and its implications for FXIa inhibition.

Jeffrey Weitz, MD, is a professor of medicine, biochemistry, and biomedical sciences at McMaster University, executive director of the Thrombosis and Atherosclerosis Research Institute in Hamilton, Ontario, and current Secretary General of the ISTH.